PORTLAND, OR – November 30, 2016 – Tricol Biomedical, Inc., a wholly owned subsidiary of Tricol International Group, Ltd., and a leading developer and marketer of the HemCon branded advanced wound care products, is inviting customers to explore its new website, available at www.tricolbiomedical.com.
.....
Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device
.....
HemCon has moved its office headquarters to downtown Portland into an innovative human centered work environment designed to foster greater connectivity between all employees, customers and stakeholders. HemCon also transitioned its manufacturing to an outsourced model in the U.S.
.....
U.S. Department of Defense’s Committee on Tactical Combat Casualty Care (CoTCCC) updated its guideline recommendations to include HemCon’s ChitoGauze hemostatic chitosan-coated gauze product.
.....
Four Dutch helicopter emergency medical teams (HEMS) used HemCon® ChitoGauze® in the field to control traumatic bleeding and recorded successful results after a minimal application time of five minutes.
.....
